MRK vs NVS vs ABBV
161 measures in 16 categories, one definition each, computed from filings and market data.
MRK48.9
Merck & Co., Inc.
Healthcare · Drug Manufacturers - General
$145.97 +0.52%$360.1B mkt cap
Score DNA
NVS64.6
Novartis AG
Healthcare · Drug Manufacturers - General
$150.62 +0.13%$286.3B mkt cap
Score DNA
ABBV66.6
AbbVie Inc.
Healthcare · Drug Manufacturers - General
$285.42 +0.71%$504.4B mkt cap
Score DNA
Price, rebased to 100 three years ago
MRK NVS ABBV · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 4 | 0 | 1 |
| Last Congress purchase | 2026-08-19 | — | 2026-05-01 |
| 13F net change in holders | +47 | — | +124 |
| ETFs adding shares, 30d | 1,877 | 41 | 1,804 |
| ETFs trimming, 30d | 1,581 | 38 | 1,578 |
| Net ETF funds, 30d | +296 | +3 | +226 |
Valuation
16 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| P/E (TTM) | 113.5x
100th
|
22.4x
20th
|
79.9x
90th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 1.01
40th
|
— |
| Price / sales | 5.4x
55th
|
5.1x
45th
|
7.8x
91st
|
| Price / book | 8.6x
70th
|
6.9x
50th
|
— |
| Price / tangible book | — | — | — |
| Price / free cash flow | 22.4x
55th
|
18.1x
45th
|
26.4x
82nd
|
| Price / operating cash flow | 18.0x
55th
|
15.6x
45th
|
25.9x
82nd
|
| Enterprise value | $406.9B
73rd
|
$327.6B
64th
|
$568.6B
82nd
|
| EV / sales | 6.1x
55th
|
5.9x
45th
|
8.8x
91st
|
| EV / EBITDA | 29.2x
82nd
|
14.7x
27th
|
26.8x
73rd
|
| EV / EBIT | 56.4x
100th
|
19.4x
20th
|
42.7x
90th
|
| EV / free cash flow | 25.3x
55th
|
20.7x
36th
|
29.8x
82nd
|
| Earnings yield | 0.9%
9th
|
4.5%
82nd
|
1.3%
18th
|
| FCF yield | 4.5%
45th
|
5.5%
55th
|
3.8%
18th
|
| Operating cash flow yield | 5.5%
45th
|
6.4%
55th
|
3.9%
18th
|
| Graham number (per share) | $22.13
22nd
|
$57.06
44th
|
— |
Profitability (TTM)
12 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Gross margin | 75.4%
73rd
|
74.3%
64th
|
71.5%
45th
|
| EBITDA margin | 20.9%
27th
|
40.0%
82nd
|
32.9%
55th
|
| Operating margin | 15.3%
18th
|
30.5%
82nd
|
29.3%
73rd
|
| EBIT margin | 10.8%
18th
|
30.4%
82nd
|
20.7%
45th
|
| Net margin | 4.8%
18th
|
22.9%
91st
|
9.8%
45th
|
| NOPAT margin | 8.1%
9th
|
25.1%
73rd
|
21.3%
55th
|
| FCF margin | 24.2%
45th
|
28.4%
73rd
|
29.7%
82nd
|
| Operating cash flow margin | 30.0%
55th
|
33.1%
82nd
|
30.3%
64th
|
| R&D / revenue | 43.7%
100th
|
20.3%
73rd
|
15.1%
9th
|
| SG&A / revenue | 16.6%
18th
|
23.6%
64th
|
22.8%
55th
|
| Stock comp / revenue | 1.0%
45th
|
1.0%
36th
|
1.5%
100th
|
| Effective tax rate | 46.7%
91st
|
17.9%
45th
|
27.4%
82nd
|
Returns on capital
11 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| ROE (on average equity) | 7.0%
30th
|
30.6%
70th
|
— |
| ROA | 2.6%
27th
|
11.3%
91st
|
4.6%
45th
|
| ROIC | 6.1%
27th
|
16.8%
55th
|
23.5%
91st
|
| ROCE | 7.1%
27th
|
18.7%
82nd
|
14.2%
45th
|
| Return on tangible assets | 5.8%
27th
|
14.9%
91st
|
9.8%
45th
|
| Cash ROIC (OCF / invested capital) | 22.5%
55th
|
22.2%
45th
|
33.4%
82nd
|
| Gross profitability (GP / assets) | 38.9%
64th
|
33.9%
45th
|
34.1%
55th
|
| ROIC, 3-yr average | 9.7%
45th
|
17.5%
82nd
|
10.8%
55th
|
| ROIC, 5-yr average | 16.2%
56th
|
19.0%
67th
|
— |
| ROE, 5-yr average | 23.8%
56th
|
30.7%
78th
|
— |
| Incremental ROIC | -29.1%
36th
|
17.2%
55th
|
-202.7%
18th
|
Growth
17 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Revenue growth (TTM YoY) | 4.5%
45th
|
0.8%
27th
|
10.4%
91st
|
| Revenue growth (QoQ) | 2.0%
9th
|
6.6%
36th
|
13.3%
82nd
|
| Revenue CAGR, 3 yr | 4.5%
55th
|
6.0%
73rd
|
4.7%
64th
|
| Revenue CAGR, 5 yr | 7.9%
64th
|
1.5%
9th
|
3.7%
55th
|
| Gross profit CAGR, 3 yr | 5.9%
45th
|
7.5%
64th
|
6.0%
55th
|
| Operating income CAGR, 3 yr | 16.7%
70th
|
22.7%
80th
|
2.8%
30th
|
| Net income growth (TTM YoY) | -80.7%
0th
|
-6.6%
50th
|
67.5%
80th
|
| Net income CAGR, 3 yr | 0.7%
40th
|
18.6%
80th
|
-10.1%
30th
|
| EPS growth (TTM YoY) | -80.3%
0th
|
-4.3%
50th
|
67.6%
70th
|
| EPS CAGR, 3 yr | 1.6%
40th
|
22.2%
80th
|
-10.1%
30th
|
| EPS CAGR, 5 yr | -10.2%
33rd
|
10.9%
78th
|
-1.0%
44th
|
| FCF growth (TTM YoY) | 9.1%
60th
|
-5.9%
20th
|
4.7%
50th
|
| FCF CAGR, 3 yr | 14.0%
64th
|
7.1%
36th
|
-8.3%
0th
|
| Operating cash flow CAGR, 3 yr | 9.8%
64th
|
6.2%
45th
|
-8.6%
0th
|
| Book value CAGR, 3 yr | 3.6%
44th
|
-4.3%
33rd
|
— |
| Dividend CAGR, 3 yr | 2.0%
60th
|
8.1%
90th
|
1.8%
50th
|
| Sustainable growth rate | -11.3%
0th
|
8.9%
33rd
|
— |
Margin history & stability
7 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Gross margin, 3-yr average | 75.9%
73rd
|
75.1%
64th
|
69.5%
45th
|
| Operating margin, 3-yr average | 24.0%
64th
|
28.3%
91st
|
24.0%
55th
|
| Net margin, 3-yr average | 17.5%
73rd
|
26.9%
91st
|
8.7%
27th
|
| FCF margin, 3-yr average | 22.8%
55th
|
28.3%
82nd
|
31.1%
91st
|
| Revenue stability (0-1) | 0.93
82nd
|
0.31
9th
|
0.72
45th
|
| Earnings stability (0-1) | 0.00
9th
|
0.00
0th
|
0.30
55th
|
| Margin stability (0-1) | 0.95
55th
|
0.96
73rd
|
0.93
45th
|
Liquidity (latest quarter)
7 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Cash & short-term investments | $7.1B
45th
|
$7.7B
55th
|
$6.6B
36th
|
| Net cash (− = net debt) | −$46.8B
18th
|
−$41.3B
45th
|
−$64.3B
0th
|
| Working capital | $8.9B
73rd
|
−$4.4B
9th
|
−$8.0B
0th
|
| Current ratio | 1.32
55th
|
0.86
9th
|
0.81
0th
|
| Quick ratio | 1.10
64th
|
0.67
0th
|
0.69
18th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.26
36th
|
0.24
27th
|
0.16
9th
|
| Defensive interval (days) | 178 days
9th
|
262 days
36th
|
274 days
45th
|
Leverage & solvency (latest quarter)
13 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Total debt | $53.9B
64th
|
$49.0B
45th
|
$70.8B
100th
|
| Debt / equity | 1.29
50th
|
1.18
40th
|
— |
| Net debt / equity | 1.12
50th
|
0.99
40th
|
— |
| Debt / assets | 41.5%
55th
|
40.2%
45th
|
52.4%
73rd
|
| Debt / capital | 56.2%
50th
|
54.1%
40th
|
— |
| Debt / EBITDA | 3.87
64th
|
2.20
27th
|
3.34
55th
|
| Net debt / EBITDA | 3.36
64th
|
1.86
27th
|
3.03
55th
|
| Interest coverage (EBIT / interest) | 5.7x
55th
|
12.2x
82nd
|
4.6x
36th
|
| Cash interest coverage | 15.8x
82nd
|
13.2x
64th
|
6.7x
27th
|
| Debt payback (years of OCF) | 2.7 yrs
45th
|
2.7 yrs
36th
|
3.6 yrs
73rd
|
| Liabilities / assets | 67.7%
45th
|
65.6%
36th
|
104.3%
100th
|
| IS credit model rating | A- | AA- | BB- |
| Implied credit spread (bps) | 175
36th
|
100
18th
|
550
91st
|
Efficiency
11 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Asset turnover | 0.54
64th
|
0.49
45th
|
0.47
36th
|
| Fixed asset turnover | 2.58
0th
|
4.54
64th
|
11.11
100th
|
| Inventory turnover | 2.5
73rd
|
2.3
64th
|
3.6
91st
|
| Receivables turnover | 5.4
82nd
|
6.0
91st
|
4.9
45th
|
| Days sales outstanding | 67 days
18th
|
61 days
9th
|
75 days
55th
|
| Days inventory outstanding | 146 days
27th
|
161 days
36th
|
100 days
9th
|
| Days payables outstanding | 88 days
18th
|
112 days
45th
|
646 days
91st
|
| Cash conversion cycle (days) | 125 days
45th
|
110 days
36th
|
−471 days
0th
|
| Capex / revenue | 5.9%
70th
|
4.6%
50th
|
0.6%
0th
|
| Capex / depreciation | 0.58
60th
|
0.48
40th
|
0.05
0th
|
| Operating expense ratio | 77.6%
91st
|
41.6%
64th
|
36.9%
18th
|
Cash flow & earnings quality
7 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Operating cash flow / net income | 6.29
100th
|
1.44
50th
|
3.09
60th
|
| FCF / net income | 5.06
100th
|
1.24
50th
|
3.02
80th
|
| FCF / operating cash flow | 80.4%
40th
|
86.0%
70th
|
97.9%
100th
|
| Capex / operating cash flow | 19.6%
60th
|
14.0%
30th
|
2.1%
0th
|
| Accruals ratio | -13.6%
9th
|
-5.0%
36th
|
-9.7%
18th
|
| Sloan accruals ratio | -7.1%
9th
|
-3.5%
45th
|
-3.9%
36th
|
| Earnings quality score (0-1) | 0.75
0th
|
1.00
30th
|
0.75
0th
|
Scores & forensic checks
15 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| IS score | 49
36th
|
65
55th
|
67
64th
|
| IS profitability | 28
9th
|
89
91st
|
62
45th
|
| IS growth | 24
27th
|
37
45th
|
76
91st
|
| IS value | 36
18th
|
46
73rd
|
32
9th
|
| IS momentum | 58
36th
|
67
45th
|
91
91st
|
| IS risk (safety) | 90
64th
|
90
64th
|
50
9th
|
| IS quality | 55
18th
|
79
64th
|
72
45th
|
| IS balance sheet | 45
45th
|
54
73rd
|
26
9th
|
| IS earnings quality | 54
9th
|
72
91st
|
59
18th
|
| IS cash flow | 71
73rd
|
71
64th
|
77
82nd
|
| Piotroski F-score (0-9) | 4
9th
|
5
18th
|
7
45th
|
| Altman Z-score | 3.6
73rd
|
3.6
64th
|
2.4
27th
|
| Beneish M-score | −2.94
18th
|
−2.53
73rd
|
−2.82
27th
|
| Ohlson O-score | −7.82
64th
|
−8.26
45th
|
−7.50
73rd
|
| IS credit score | 66
64th
|
82
82nd
|
40
9th
|
Size (TTM)
8 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| Market cap | $360.1B
73rd
|
$286.3B
64th
|
$504.4B
82nd
|
| Revenue | $66.5B
82nd
|
$55.6B
45th
|
$64.4B
73rd
|
| EBITDA | $13.9B
36th
|
$22.3B
82nd
|
$21.2B
73rd
|
| Net income | $3.2B
27th
|
$12.8B
82nd
|
$6.3B
45th
|
| Free cash flow | $16.1B
73rd
|
$15.8B
64th
|
$19.1B
91st
|
| Total assets | $129.8B
64th
|
$122.0B
55th
|
$135.1B
73rd
|
| Shareholders' equity | $41.9B
73rd
|
$41.5B
64th
|
−$5.9B
0th
|
| Employees | 74,000
64th
|
75,267
82nd
|
57,000
55th
|
Price performance
9 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| 1 day | +0.5% | +0.1% | +0.7% |
| 1 week | +0.2% | +4.8% | +3.9% |
| 1 month | −0.8% | +6.8% | +8.1% |
| 3 months | +17.3% | +0.7% | +12.7% |
| 6 months | +22.6% | −0.9% | +37.0% |
| Year to date | +37.1% | +8.7% | +25.5% |
| 1 year | +75.0% | +15.9% | +26.2% |
| 3 years, cumulative | +51.5% | +61.1% | +107.1% |
| 5 years, cumulative | +106.7% | +115.6% | +201.3% |
Technicals
4 measures| Measure | MRK | NVS | ABBV |
|---|---|---|---|
| RSI 14 | 52.0 | 62.4 | 71.1 |
| From 52-week high | −7.0% | −10.3% | −2.0% |
| From 52-week low | +79.5% | +23.9% | +49.6% |
| Beta | 0.22 | 0.42 | 0.28 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17